Jaguar Health executed multiple equity transactions in mid-September 2026 to raise capital and consolidate ownership of its Italian subsidiary, Napo Therapeutics. On September 11, the company exchanged a $175,016.36 convertible promissory note held by Lincoln Alternative Strategies for 557,377 shares of common stock. Simultaneously, it converted Series Q Preferred Stock held by Streeterville Capital into 304,473 total common shares across three agreements dated July 7, September 11, and September 14. Additionally, on September 12, Jaguar Health entered a securities purchase agreement to acquire the remaining minority stake in Napo Therapeutics from a related party by issuing 535,000 common shares and a pre-funded warrant for 2,077,255 shares; this transaction closed on September 15. These actions represent significant unregistered equity issuances and strategic consolidation of its pharmaceutical subsidiary.

Jaguar Health, Inc. effected a one-for-fifteen (15) reverse stock split of its common stock on September 17, 2026, to maintain compliance with Nasdaq listing standards. The company filed the Twelfth Amendment to its Certificate of Incorporation in Delaware on September 14, 2026, following shareholder approval at a special meeting held on April 20, 2026. Under the split, every fifteen shares were reclassified into one share without changing par value or authorized share count; fractional shares are cashed out. Outstanding options and warrants saw proportional reductions in share counts and increases in exercise prices. The company operates in the pharmaceutical industry, developing prescription drugs derived from plants for gastrointestinal diseases.

Jaguar Health reported second-quarter 2026 financial results showing a net loss of $12.7 million, or $15.68 per share, compared to a $10.4 million loss in the prior year period. Total revenue decreased 59% to $1.2 million, driven by a 60% drop in prescription product sales as commercial rights for Mytesi and Canalevia-CA1 were licensed to Future Pak. The company recognized $43,000 in license fees from a European partner and received the final $2 million holdback payment under its U.S. licensing agreement with Future Pak. Operating expenses decreased by approximately $2.1 million due to the dissolution of the Jaguar/Napo sales group, though R&D costs rose slightly to support crofelemer powder formulation development for rare intestinal failure diseases. The company expects to submit a New Drug Application for microvillus inclusion disease in Q2 2027. Jaguar Health develops novel prescription drugs derived from plants for gastrointestinal disorders.

Jaguar Health, Inc. announced that its subsidiary, Napo Pharmaceuticals, Inc., and Alivus Life Sciences Limited (f/k/a Glenmark Life Sciences Limited) entered into a new manufacturing and supply agreement for crofelemer, the active ingredient in Mytesi, which expires on March 31, 2029. The agreement includes minimum purchase commitments from Napo, subject to certain shortfall obligations and capacity constraints. Jaguar Health, Inc. operates in the healthcare industry, developing and commercializing human prescription drug products.

Jaguar Health, Inc. completed the conversion of its Series O Preferred Stock into Common Stock at a conversion ratio of 3.209 shares of Common Stock for each share of Series O Preferred Stock on June 25, 2026. Following the conversion, there were 4,857,211 shares of Common Stock issued and outstanding. Jaguar Health, Inc. operates in the healthcare industry and develops medical devices and supplements for gastrointestinal health.